Coop Pank AS has updated its European Medium Term Note and Covered Bond Programme, increasing the programme limit to EUR 1.5 billion and adding senior notes and subordinated notes alongside covered bonds.
ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing Milestone
Strong First-Half Performance with Sales up 16.7% as profit after tax doubled in 1H 2026 Sales for 1H 2026: €273.0m, up 16.7% from 1H 2025 Net margin for 1H 2026: €23.7m, up
The Company’s net turnover in 2022 was 1.6 million euros, which is by 168 thousand euros or 12.1% bigger than in 2021. The proportion of the revenue from the Company’s basic economic
Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management. Date on
CoinShares XBT Provider AB (publ)LEI: 549300HGWKR2Q5T8GK64 3 September 2026 CoinShares XBT Provider AB (publ) Issuance Programme for the issue of Bitcoin Tracker Certificates and Ethereum Tracker Certificates Change of FX Rate/FX Source
AS LHV Group announces that during the period 11 September to 17 September 2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows: Date Aggregated volume (pcs) Weighted average price
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation (“Orion Pharma”) and Qilu Pharma Europe
The Management Board of Joint Stock Company ‘Siguldas ciltslietu un mākslīgās apsēklošanas stacija’ (unified reg. No. 40003013295, legal address: ‘Kalnabeites 8’, Sigulda, Sigulda area, LV-2150) announces that regular shareholders’ meeting of the
In accordance with the initiative and decision of the Board of New Energy Group EPSO-G (legal entity code 302826889, registered address Laisvės pr. 10, Vilnius, Lithuania) the Extraordinary General Meeting of EPSO-G
Follow